{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:58Z","timestamp":1786982758723,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40264-025-01523-y","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:18:35Z","timestamp":1742372315000},"page":"697-713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pregnancy and Infant Outcomes in Women with Multiple Sclerosis Exposed to Glatiramer Acetate Therapy: An Extended 4-Year Safety Update"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3352-8480","authenticated-orcid":false,"given":"Sigal","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra","family":"Ghimpeteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Florentina","family":"Dragut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"1523_CR1","unstructured":"Teva Pharmaceuticals Ltd. Copaxone\u00ae (glatiramer acetate) 20 & 40 mg\/ml solution for injection in pre-filled syringe: summary of product characteristics. 2022. Available from https:\/\/www.medicines.org.uk\/emc\/product\/183\/smpc and https:\/\/www.medicines.org.uk\/emc\/product\/7046\/smpc. Accessed 3 Aug 2024."},{"key":"1523_CR2","unstructured":"Teva Neuroscience Inc. COPAXONE\u00ae (glatiramer acetate injection): US Prescribing Information. ***November 2023. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/020622s116lbl.pdf. Accessed 1 Aug 2024."},{"issue":"12","key":"1523_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1471-2377-12-124","volume":"22","author":"M Giannini","year":"2012","unstructured":"Giannini M, Portaccio E, Ghezzi A, Hakiki B, Past\u00f2 L, Razzolini L, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012;22(12):124.","journal-title":"BMC Neurol"},{"issue":"5","key":"1523_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1756285612453192","volume":"5","author":"K Hellwig","year":"2012","unstructured":"Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012;5(5):247\u201353.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"1523_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1177\/1352458515623366","volume":"22","author":"S Herbstritt","year":"2016","unstructured":"Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Scler. 2016;22(6):810\u20136.","journal-title":"Mult Scler"},{"issue":"4","key":"1523_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/pds.4735","volume":"28","author":"SC MacDonald","year":"2019","unstructured":"MacDonald SC, McElrath TF, Hern\u00e1ndez-D\u00edaz S. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis. Pharmacoepidemiol Drug Saf. 2019;28(4):556\u201360.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1523_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.msard.2019.01.003","volume":"28","author":"AL Nguyen","year":"2019","unstructured":"Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study. Mult Scler Relat Disord. 2019;28:235\u201343.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"1523_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7224\/1537-2073.2016-079","volume":"20","author":"M Sandberg-Wollheim","year":"2018","unstructured":"Sandberg-Wollheim M, Neudorfer O, Grinspan A, Weinstock-Guttman B, Haas J, Izquierdo G, et al. Pregnancy outcomes from the branded glatiramer acetate pregnancy database. Int J MS Care. 2018;20(1):9\u201314.","journal-title":"Int J MS Care"},{"issue":"10","key":"1523_CR9","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1177\/13524585221083982","volume":"28","author":"AI Ciplea","year":"2022","unstructured":"Ciplea AI, Kurzeja A, Thiel S, Haben S, Alexander J, Adamus E, et al. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis\u2014COBRA study. Mult Scler. 2022;28(10):1641\u201350.","journal-title":"Mult Scler"},{"issue":"4","key":"1523_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40264-022-01168-1","volume":"45","author":"S Kaplan","year":"2022","unstructured":"Kaplan S, Zeygarnik M, Stern T. Pregnancy, fetal, and infant outcomes following maternal exposure to glatiramer acetate during pregnancy and breastfeeding. Drug Saf. 2022;45(4):345\u201357.","journal-title":"Drug Saf"},{"key":"1523_CR11","unstructured":"European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP): product- or population-specific considerations III: pregnant and breastfeeding women. 2019. Available from https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-good-pharmacovigilance-practices-product-population-specific-considerations-iii_en.pdf. Accessed 3 Aug 2021."},{"key":"1523_CR12","unstructured":"University of California San Francisco (UCSF) Health. Pregnancy: the three trimesters. 2020. Available from https:\/\/www.ucsfhealth.org\/conditions\/pregnancy. Accessed 25 Feb 2025."},{"issue":"9","key":"1523_CR13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/bdra.20842","volume":"91","author":"LB Holmes","year":"2011","unstructured":"Holmes LB, Westgate MN. Inclusion and exclusion criteria for malformations in newborn infants exposed to potential teratogens. Birth Defects Res A Clin Mol Teratol. 2011;91(9):807\u201312.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"1523_CR14","unstructured":"Centers for Disease Control and Prevention (CDC). Metropolitan Atlanta Congenital Defects Program (MACDP). https:\/\/www.cdc.gov\/birth-defects\/tracking\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/ncbddd\/birthdefects\/macdp.html. Accessed 25 Feb 2025."},{"key":"1523_CR15","unstructured":"European network for surveillance of congenital anomalies (EUROCAT). European surveillance of congenital anomalies (EUROCAT) Guide 1.4 and reference documents. 2018. Available from https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/Full_Guide_1_4_version_28_DEC2018.pdf. Accessed 29 Aug 2021."},{"issue":"1","key":"1523_CR16","first-page":"1","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","unstructured":"Centers for Disease Control and Prevention. Update on overall prevalence of major birth defects\u2013Atlanta, Georgia, 1978\u20132005. MMWR Morb Mortal Wkly Rep. 2008;57(1):1\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1523_CR17","unstructured":"EUROCAT. European network for surveillance of congenital anomalies (EUROCAT)\u2014prevalence charts and tables. Available from https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/eurocat-data\/prevalence_en. Accessed 24 May 2023."},{"issue":"5","key":"1523_CR18","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/art.27358","volume":"62","author":"CD Chambers","year":"2010","unstructured":"Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62(5):1494\u2013503.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1523_CR19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.38368","volume":"66","author":"C Weber-Schoendorfer","year":"2014","unstructured":"Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101\u201310.","journal-title":"Arthritis Rheumatol"},{"key":"1523_CR20","unstructured":"Robert Koch Institute. Reference percentiles for anthropometric measures and blood pressure based on the German Health Interview and Examination Survey for Children and Adolescents 2003\u20132006 (KiGGS). 2016. https:\/\/edoc.rki.de\/bitstream\/handle\/176904\/3271\/23s3ntHQtKbus.pdf?sequence=1&isAllowed=y. Accessed 25 Feb 2025."},{"key":"1523_CR21","unstructured":"MSD and the MSD Manuals. WHO infant weight for length percentiles (<24 months). 2022 [cited 2022 January 28]. Available from https:\/\/www.msdmanuals.com\/professional\/multimedia\/clinical-calculator\/who-infant-weight-for-length-percentiles-24-months. Accessed 24 May 2023."},{"issue":"2","key":"1523_CR22","first-page":"1","volume":"73","author":"MJK Osterman","year":"2024","unstructured":"Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: final data for 2022. Natl Vital Stat Rep. 2024;73(2):1\u201356.","journal-title":"Natl Vital Stat Rep"},{"issue":"1","key":"1523_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ppe.12417","volume":"32","author":"LM Rossen","year":"2018","unstructured":"Rossen LM, Ahrens KA, Branum AM. Trends in risk of pregnancy loss among US women, 1990\u20132011. Paediatr Perinat Epidemiol. 2018;32(1):19\u201329.","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"29","key":"1523_CR24","first-page":"1","volume":"47","author":"SJ Ventura","year":"1999","unstructured":"Ventura SJ, Mosher WD, Curtin SC, Abma JC, Henshaw S. Highlights of trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976\u201396. Natl Vital Stat Rep. 1999;47(29):1\u20139.","journal-title":"Natl Vital Stat Rep"},{"issue":"2","key":"1523_CR25","first-page":"1","volume":"70","author":"JA Martin","year":"2021","unstructured":"Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: final data for 2019. Natl Vital Stat Rep. 2021;70(2):1\u201351.","journal-title":"Natl Vital Stat Rep"},{"issue":"9","key":"1523_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jnnp-2022-330883","volume":"94","author":"M Moccia","year":"2023","unstructured":"Moccia M, Affinito G, Fumo MG, Giordana R, Di Gennaro M, Mercogliano M, et al. Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020. J Neurol Neurosurg Psychiatry. 2023;94(9):689\u201397.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"1523_CR27","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1007\/s00415-010-5652-y","volume":"257","author":"HJ Salminen","year":"2010","unstructured":"Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol. 2010;257(12):2020\u20133.","journal-title":"J Neurol"},{"key":"1523_CR28","unstructured":"Hallare J, Gerriets V. Half Life. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing LLC.; 2022."},{"issue":"1","key":"1523_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40120-021-00297-6","volume":"11","author":"L Lorefice","year":"2022","unstructured":"Lorefice L, Fronza M, Fenu G, Frau J, Coghe G, D\u2019Alterio MN, et al. Effects of pregnancy and breastfeeding on clinical outcomes and MRI measurements of women with multiple sclerosis: an exploratory real-world cohort study. Neurol Ther. 2022;11(1):39\u201349.","journal-title":"Neurol Ther"},{"issue":"3","key":"1523_CR30","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s00415-010-5758-2","volume":"258","author":"K Hellwig","year":"2011","unstructured":"Hellwig K, Gold R. Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol. 2011;258(3):502\u20133.","journal-title":"J Neurol"},{"issue":"3","key":"1523_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neurol.2020.05.005","volume":"177","author":"S Vukusic","year":"2021","unstructured":"Vukusic S, Michel L, Leguy S, Lebrun-Frenay C. Pregnancy with multiple sclerosis. Rev Neurol (Paris). 2021;177(3):180\u201394.","journal-title":"Rev Neurol (Paris)"},{"issue":"3","key":"1523_CR32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/13524585211023365","volume":"28","author":"E Portaccio","year":"2022","unstructured":"Portaccio E, Tudisco L, Past\u00f2 L, Razzolini L, Fonderico M, Bellinvia A, et al. Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Mult Scler. 2022;28(3):472\u20139.","journal-title":"Mult Scler"},{"issue":"12","key":"1523_CR33","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1111\/ene.16036","volume":"30","author":"S Kaplan","year":"2023","unstructured":"Kaplan S, Zeygarnik M, Stern T, Hellwig K. Pregnancy and fetal outcomes following maternal exposure to glatiramer acetate in all three trimesters of pregnancy. Eur J Neurol. 2023;30(12):3890\u20135.","journal-title":"Eur J Neurol"},{"issue":"5","key":"1523_CR34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1017\/S0007114508864835","volume":"99","author":"M Kohlhuber","year":"2008","unstructured":"Kohlhuber M, Rebhan B, Schwegler U, Koletzko B, Fromme H. Breastfeeding rates and duration in Germany: a Bavarian cohort study. Br J Nutr. 2008;99(5):1127\u201332.","journal-title":"Br J Nutr"},{"key":"1523_CR35","unstructured":"MICH. Increase the proportion of infants who are breastfed exclusively through age 6 months\u2014MICH-15 healthy people 2030. 2020. Available from https:\/\/health.gov\/healthypeople\/objectives-and-data\/browse-objectives\/infants\/increase-proportion-infants-who-are-breastfed-exclusively-through-age-6-months-mich-15. Accessed 1 Aug 2024."},{"issue":"1","key":"1523_CR36","first-page":"12","volume":"28","author":"RM Bove","year":"2022","unstructured":"Bove RM, Houtchens MK. Pregnancy management in multiple sclerosis and other demyelinating diseases. Continuum (Minneap Minn). 2022;28(1):12\u201333.","journal-title":"Continuum (Minneap Minn)"},{"key":"1523_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104771","volume":"75","author":"AI Ciplea","year":"2023","unstructured":"Ciplea AI, Kurzeja A, Thiel S, Haben S, Adamus E, Hellwig K. Safety evaluations of offspring breastfed by mothers receiving glatiramer acetate for relapsing multiple sclerosis. Mult Scler Relat Disord. 2023;75: 104771.","journal-title":"Mult Scler Relat Disord"},{"issue":"17","key":"1523_CR38","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388.","journal-title":"Neurology"},{"issue":"2","key":"1523_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.13536","volume":"25","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25(2):215\u201337.","journal-title":"Eur J Neurol"},{"issue":"27","key":"1523_CR40","first-page":"3","volume":"2021","author":"ECTRIMS","year":"2021","unstructured":"ECTRIMS. Oral presentations. Mult Scler. 2021;2021(27):3\u2013133.","journal-title":"Mult Scler"},{"key":"1523_CR41","unstructured":"Medscape. Updated MS Guidelines Advocate Earlier, More Aggressive Treatment. 2021 [cited 2024 September 5]. Available from https:\/\/www.medscape.com\/viewarticle\/961161#vp_1. Accessed 5 Sept 2024."},{"issue":"4","key":"1523_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1017\/cjn.2020.66","volume":"47","author":"MS Freedman","year":"2020","unstructured":"Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC, et al. Treatment optimization in multiple sclerosis: Canadian MS working group recommendations. Can J Neurol Sci. 2020;47(4):437\u201355.","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"1523_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/13524585221129472","volume":"29","author":"S Vukusic","year":"2023","unstructured":"Vukusic S, Carra-Dalliere C, Ciron J, Maillart E, Michel L, Leray E, et al. Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society. Mult Scler. 2023;29(1):11\u201336.","journal-title":"Mult Scler"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01523-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01523-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01523-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T09:48:11Z","timestamp":1747907291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01523-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1523"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01523-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"29 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis was funded by Teva Pharmaceutical Industries Ltd and\/or its affiliates.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sigal Kaplan, Andra Ghimpeteanu, and Claudia Florentina Dragut are employees of Teva Pharmaceutical Industries Ltd., or its affiliates.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The analyses were conducted retrospectively using de-identified patient data as part of a regulatory commitment. Therefore, ethical approval and informed consent were not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The original contributions in this analysis are included in this published article and its supplementary information files. The authors have full access to all data in the analysis and take full responsibility for the integrity, accuracy, and conduct of the research.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SK: study supervision, analysis, interpretation of data, drafting of manuscript. AG: data acquisition, analysis. CFD: study supervision, analysis, interpretation of data. All authors reviewed and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}},{"value":"The views expressed in this article are those of the authors and do not necessarily reflect those of Teva Pharmaceutical Industries Ltd. and\/or its affiliates.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}